E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057840 |
E.1.2 | Term | Major depression |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in subjects with MDD partially responsive to SSRI/SNRI treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in subjects with MDD partially responsive to SSRI/SNRI treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in both responders and non-responders during the placebo lead-in period. - To investigate the overall safety and tolerability of treatment with adjunctive JNJ 67953964 in subjects with MDD when used in combination with a SSRI or SNRI. - To investigate the effect of JNJ-67953964 versus placebo on depression related anhedonia as assessed by the Snaith-Hamilton Pleasure Scale (SHAPS).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects must be men or women, 18 to 64 years of age, inclusive. Note: Subjects should be at least 18 years of age or older as per the legal age of consent in the jurisdiction in which the study is taking place. 2. Have a Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive (BMI = weight/height2). 3. Subjects must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead ECG performed at screening and baseline (Visit 2) For clinical laboratory tests only screening results will be considered. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed once during the screening phase. In 12-lead ECG, QTcF should be ≤ 450 msec for males or ≤ 470 msec for females and PR interval < 220 msec at screening. A retest of an abnormal ECG value will be allowed once in the screening phase. Blood pressure will be the average of 2 measurements. The subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator. 4. Population specific: - Subjects must have a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD. Subjects with a diagnosis of comorbid Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), or Panic Disorder may be included, if the investigator considers MDD to be the primary diagnosis (confirmed by an independent central rater through review of the MINI interview obtained by the site at screening). The current episode should be less than 18 months. - Subjects must be currently treated with an SSRI/SNRI antidepressant approved in this protocol (see Section 6.5) at an adequate dose, as defined by the ATRQ, and for at least 6 continuous weeks but not more than 12 months. - Have a MADRS total score ≥25 at screening. If 2 weeks or more elapse between the MADRS rating at screening and Visit 2, the local rater will complete the MADRS again by a telephone interview up to 4 days before Visit 2. At this telephone interview, MADRS total score should again be ≥25 and should not demonstrate a clinically significant change (i.e., an improvement of >20%). - In a common population of subject suffering from MDD, about 90% have a SHAPS total score >20. The SHAPS total score will initially not be an inclusion criterion. However, after 50 subjects have been randomized, the subjects’ properties will be reviewed. If less than 50% of non-responding subjects have a SHAPS total score >20, then for the remaining subjects the following inclusion criterion will be added: - Have a SHAPS total score >20 at screening and baseline (Visit 2) 5. Men who are sexually active with a woman of childbearing potential and have not had a vasectomy must agree to use a barrier method of birth control e.g., either condom or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository for the duration of the study plus 3 months after receiving the last dose of study drug, and all men must not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partners should also use an additional method of birth control (which may include a hormonal method, an intrauterine device [IUD] or an intrauterine system [IUS]) for at least the same duration.
|
|
E.4 | Principal exclusion criteria |
1. Has current signs/symptoms of, liver or renal insufficiency, hypothyroidism or hyperthyroidism (a normal thyroid-stimulating function is required at screening; subjects who are on stable treatment with thyroid supplementation with normal thyroid-stimulating hormone [TSH] may participate but subjects with thyroid supplementation for antidepressant purposes are not allowed in the study*), significant cardiac disease (including current or past history of atrial fibrillation/flutter), vascular, pulmonary, endocrine, neurologic (including epilepsy), hematologic, inflammatory (e.g., rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease) or metabolic disturbances. Diabetes mellitus (DM) may be allowed when the subject is stable (HbA1c less than 7.5% or 58 mmol/mol). *Subjects with known hypothyroidism who have been on stable treatment for at least 3 months prior to screening are required to have TSH and free thyroxine (FT4) obtained. Any subject with an elevated TSH should also have FT4 measured. In any case where the TSH value is out of range, but FT4 is normal, the findings should be discussed directly with the medical monitor before the subject is enrolled. If the FT4 value is out of range, the subject is not eligible. 2. History of documented gastric disease (including documented peptic ulcer disease, gastritis, upper GI bleeding, esophagitis, or any GI precancerous condition), current clinically evident GI complaints. 3. Chronic use of a proton pump inhibitors (PPIs). History of incidental use of PPIs is allowed but should have been stopped at least 4 weeks before screening. A history of chronic nonsteroidal anti-inflammatory drug (NSAID) or aspirin use. (Low dose aspirin e.g. in cardiovascular disease prevention is allowed). 4. Has a history of alcohol use disorder within the past year. 5. Criterion modified by Amendment INT-1 and INT-2. 5.2. Has failed (no more than 25% response on ATRQ) three or more antidepressant treatments including the current SSRI/SNRI during the current depressive episode despite an adequate dose (per ATRQ) and duration (at least 6 weeks).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
MADRS total score at the end of double blind treatment period in subjects not responding to placebo |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of double blind period. This is after 6 weeks of treatment. |
|
E.5.2 | Secondary end point(s) |
- MADRS total score at the end of double blind treatment period in all randomized subjects. -SHAPS-score at the end of double blind treatment period. -CGI-S, SMDDS and SATE-score at the end of double blind treatment period. - Haimilton anxiety and HAM-A6-score at the end of double blind treatment period. - safety during complete study period.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of double blind period. And safety during complete study period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
With placebo run-in and run-out period of variable duration (blinded). |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Moldova, Republic of |
Russian Federation |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |